EUVIMEDEUVIMED entdecken
Crossref

Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment

Yuncui Yu iD, Wang Cao, Yue Xiao, Ang Li, Huijie Huang, Kejun Liu, Lihua Hu, Xiaoling Hou, Li Xiang, Xiaoling Wang

Pediatric Pulmonology · 2023

DOI: 10.1002/ppul.26647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Yuncui Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, National Clinical Research Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, Nation…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Respiratory Research Project of the National Clinical Research Center for Respiratory Diseases, Asthma medication evaluation project in children commissioned by the Beijing Medical and Health Economic Research Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The study aims to compare the real‐world effectiveness and economy of the budesonide/formoterol reliever and maintenance therapy (SMART) with fixed‐dose inhaled corticosteroids (ICS)/long‐acting b‐agonist (LABA) or ICS alone plus as‐needed, short‐acting β2 agonists (SABA) in pediatric patients.

Methods

The outpatient data warehouse of a hospital in China was used. A total of 103 patients under 18 years old in the SMART group and 63 patients in the control group were included from January 1, 2020 to December 31, 2021. The effectiveness was assessed using asthma attacks and lung function at baseline, 6 months and 12 months follow‐up. Cost‐effectiveness analysis was performed with a three‐state Markov model from the healthcare system perspective. One‐way sensitivity analyses and probabilistic sensitivity analyses were performed to check the robustness of the results.

Results

The SMART regimen was more effective than other strategies in reducing the risk of mild and severe attacks in the real‐life management of childhood asthma. Patients in both groups showed significant improvement in lung function at 6 and 12 months in contrast to baseline. Compared with other strategies, the forced expiratory volume in 1 s (FEV 1 ) level in the SMART group was markedly improved at 6 months. The total cost of outpatient service using the SMART regimen was lower than that of other strategies, while the drug costs were similar in different groups. Incremental cost‐effectiveness analysis results showed that using the SMART regimen reduced the total cost by approximately CNY 10,516.11 per year with a 0.12 quality‐adjusted life year (QALYs) increase. Sensitive analyses supported that the SMART regimen was the dominant choice at the willingness‐to‐pay threshold of CNY 85,698, per capita GDP in China.

Conclusions

Collectively, our findings indicate that the real‐world effectiveness and economy of the SMART regimen are superior to the traditional strategies in pediatric asthma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsHumansChildAdolescentBudesonideEthanolaminesDrug CombinationsBudesonide, Formoterol Fumarate Drug CombinationAdrenal Cortex HormonesAdministration, InhalationFormoterol FumarateBronchodilator Agents

Stichwörter der Autor:innen

SMARTasthmabudesonide/formoteroleconomic assessmentreal-world data

Substanzen

BudesonideEthanolaminesDrug CombinationsBudesonide, Formoterol Fumarate Drug CombinationAdrenal Cortex HormonesFormoterol FumarateAnti-Asthmatic AgentsBronchodilator Agents

Autor:innen und Institutionen

  • Clinical Research Center, National Clinical Research Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • National Health Development Research Center, National Health Commission, Beijing, China.
  • Department of Allergy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID-Profile: Yuncui Yu

Förderung

  • Respiratory Research Project of the National Clinical Research Center for Respiratory Diseases
  • Asthma medication evaluation project in children commissioned by the Beijing Medical and Health Economic Research Association

Zitieren

APA

Yu, Y., Cao, W., Xiao, Y., Li, A., Huang, H., Liu, K., Hu, L., Hou, X., Xiang, L., & Wang, X. (2023). Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26647

Vancouver

Yu Y, Cao W, Xiao Y, Li A, Huang H, Liu K, et al. Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26647

BibTeX
@article{Yu2023,
  author = {Yu, Yuncui and Cao, Wang and Xiao, Yue and Li, Ang and Huang, Huijie and Liu, Kejun and Hu, Lihua and Hou, Xiaoling and Xiang, Li and Wang, Xiaoling},
  title = {Budesonide/formoterol maintenance and reliever therapy in childhood asthma: Real‐world effectiveness and economic assessment},
  journal = {Pediatric Pulmonology},
  year = {2023},
  doi = {10.1002/ppul.26647}
}
Kostenlos starten →